Table 3.
Medical therapy during in-hospital stay Values are percentage (%)
| All | Group 1 - No AF | Group 2 - New onset AF | p | |
|---|---|---|---|---|
| Aspirin | 98.6 | 98.6 | 99.2 | 0.349 |
| Clopidogrel | 86.7 | 86.6 | 89.3 | 0.138 |
| Ticagrelor | 17.6 | 17.9 | 12.3 | 0.042 |
| Prasugrel | 0 | 0 | 0 | |
| Other AP | 5.4 | 5.5 | 5.2 | 0.859 |
| GPIIbIIIa inhibitors | 33.6 | 33.5 | 35.8 | 0.362 |
| UFH | 46.3 | 46.3 | 45.6 | 0.784 |
| Fondaparinux | 6.1 | 6.0 | 7.7 | 0.185 |
| Bivalirudin | 0.7 | 0.6 | 0.8 | 0.512 |
| LMWH | 45.1 | 44.3 | 58.2 | < 0.001 |
| Vitamin K antagonists | 1.3 | 1.0 | 5.2 | < 0.001 |
| NOAC | 0.3 | 0.3 | 0.8 | 0.106 |
| Beta-blockers | 79.6 | 80.2 | 69.5 | < 0.001 |
| ACE inhibitors/ARB | 86.3 | 86.6 | 80.8 | 0.002 |
| Aldosterone antagonists | 13.5 | 12.6 | 27.3 | < 0.001 |
| Statins | 94.6 | 94.5 | 95.6 | 0.364 |
| Diuretics | 25.1 | 23.0 | 58.5 | < 0.001 |
| Amiodarone | 6.5 | 2.9 | 65.9 | < 0.001 |
| Other antiarrhythmic drugs | 1.0 | 0.9 | 1.9 | 0.08 |
| Digitalis | 0.9 | 0.3 | 11.3 | < 0.001 |
| Inotropes | 7.8 | 6.6 | 27.3 | < 0.001 |
| Levosimendan | 1.0 | 0.7 | 5.5 | < 0.001 |
AF: atrial fibrillation; AP: antiplatelet therapy; GpIIb/IIIA inhibitors: Glycoprotein IIb/IIIa inhibitors; LMWH: low molecular weight heparin; UFH: unfractionated heparin.